Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
As both TB-500 and BPC-157 peptides appear to exhibit similar pharmacological potential, when blended together, the potential action of both may be maximized what would otherwise occur with one peptide, might occur at a better, faster rate when combined
Reconstitute on day 14 of a vial's life and the peptide solution is capped at 14 days, even if the peptide would otherwise stay stable longer
This makes the injection ideal for individuals with chronic tiredness, high stress, or demanding work schedules
Composition CJC-1295 (Without DAC): 5 mg Ipamorelin: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models Assessment of assay development, including chromatographic separation of co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability